Pfizer Ltd. has entered into a marketing and supply agreement with Mylan Pharmaceuticals for the marketing and sale of two of its prominent brands, Ativan and Pacitane.

The agreement, approved by Pfizer's Board of Directors during a meeting, is set to strengthen the distribution and in-clinic presence of these medications across India.

Mylan’s strong presence in the Central Nervous System (CNS) therapy area, along with its skilled resources for engaging with specialists like neurologists and psychiatrists, is expected to enhance accessibility and market reach.

Under the terms of the agreement, Pfizer will retain ownership of the brands, while Mylan will be responsible for their marketing and sales within India for a period of five years. The commercial terms of the agreement remain undisclosed.

This collaboration is expected to boost Pfizer’s market penetration while leveraging Mylan’s expertise in the CNS segment.